Ibex Therapeutics is a clinical stage Swiss company, developing an innovative mouthwash containing medicinal plant extracts and a portfolio of products to prevent and treat chemoradiotherapy-induced oral mucositis and oral candidiasis in patients with cancer. Ibex Therapeutics has an exclusive license of Pharmalp’s patent in the field of oral health and peri-oncology. The galenic formulation is already developed for a mouthwash with a foreseen regulatory status of phyto drug. A pilot clinical study “proof-of-concept” has demonstrated a rapid decrease of oral mucositis from grade 4 to 2. A regulatory advice is ongoing, and the pivotal clinical study for registration is under preparation.